ClinicalTrials.gg
Status unknownNCT01761942FASANUpdated Jan 7, 2013

Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa

A Phase 2 interventional study of fatty acids preparation- eye-q in Anorexia Nervosa, sponsored by Institute of Psychiatry and Neurology, Warsaw. Status unknown at 1 site in Poland. Open to female participants aged 12 Years to 19 Years. Per ClinicalTrials.gov, last updated 2013-01-07.

Sponsored by Institute of Psychiatry and Neurology, Warsaw · Phase 2, Interventional, and Treatment

How we know · 3 judgments

The sponsor has not verified this record recently (last verified Jan 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 19 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether omega -3 fatty acids are effective and safe in treating anorexia nervosa.

Read the detailed description

10-week, randomized, placebo-controlled, parallel-group study to compare the efficacy and safety of omega-3 fatty acids with placebo in the treatment of anorexia nervosa. Patients will be randomly assigned to blinded study treatment. Double-blind treatment will be preceded by a medication washout period of 1-28 days if necessary. Some patients may be taking anti-depressants or anti-psychotics, e.g. fluoxetine, prior to admission to the study. In such case the wash out period will depend on the medical treatment (dependent on the drug given) given prior to qualification to the study. Patient will be treated as inpatients during 10 weeks of the study. The study will recruit female inpatients with anorexia nervosa (aged 12 to 19 years), with DSM-IV and ICD-10 diagnosis of anorexia nervosa.BMI below 5 percentile and EAT-26 score > 30 is required at both screening and randomization.

02

Conditions studied

  • Anorexia Nervosa

Browse trials for

Keywords

  • omega-3 fatty acids
  • anorexia nervosa
  • efficacy
  • safety
03

In context

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

This study's planned enrollment of 60 is above the median of 46 across 314 interventional studies indexed under Anorexia Nervosa.

Browse Anorexia Nervosa studies →

Lead sponsor

Institute of Psychiatry and Neurology, Warsaw is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 19 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anorexia nervosa (DSM IV,ICD-10)
  • Female
  • Age 12-19
  • Written given by patient and his parents

Exclusion criteria

Exclusion Criteria:

  • Lack of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    placebo ,anorexia nervosa

    2x3 placebo capsules with olive oil

  • Experimental
    fatty acids preparation- eye-q

    2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).

    Dietary Supplement: fatty acids preparation- eye-q

Interventions

  • Dietary supplementfatty acids preparation- eye-q

    3x2 tablets daily by 70 days

06

What researchers measure

Primary outcomes

  1. Omega-3 fatty acids are superior to placebo in increasing BMI at day 70 compared with baseline

    The primary objective of this study is to compare the efficacy of EPA fatty acids with that of placebo as add-on treatment for inpatients with anorexia nervosa, as assessed by the change from baseline to day 70 in BMI (body mass index)

    Time frame: day 70th

Secondary outcomes

  1. reducing EAT -26

    1. To compare the effects of omega-3/6 fatty acids with the effect of placebo in reducing EAT-26 (Eating Attitude Test-26) total score at day 70 compared with baseline

    Time frame: day 70th

  2. changes in CGI

    to compare the effects of fatty acids with the effect of placebo by change from baseline to day 70 in CGI (Clinical Global Impression)

    Time frame: day 70th

  3. change in HDRS

    to compare the effects of fatty acids with the effect of placebo on change form baseline to day 70 in Hamilton Depression Rating Scale

    Time frame: day 70 th

  4. changes in BDI

    to compare the effects of fatty acids with the effect of placebo by change form baseline to day 70 in Beck Depression Inventory

    Time frame: day 70th

  5. changes in YBOCS

    to compare the effects of fatty acids with the effect of placebo by changes in Yale-Brown Obsessive-Compulsive Scale

    Time frame: day 70 th

  6. changes in YBOCS

    to compare the effects of fatty acids with the effect of placebo by change form baseline to day 70 Yale-Brown Obsessive-Compulsive Scale

    Time frame: day 70th

  7. adverse events

    to evaluate the safety and tolerability of omega-3 fatty acids compared with placebo in the treatment of anorexia nervosa, as assessed by incidence and nature of adverse events

    Time frame: 70 days time

  8. clinical laboratory tests

    to evaluate the safety and tolerability of omega-3 fatty acids compared with placebo in the treatment of anorexia nervosa, as assessed by changes from baseline to day 70 in clinical laboratory tests (lipids metabolism - triglycerides, HDL and LDL cholesterol)

    Time frame: day 70 th

07

Study locations

1 of 1 sites recruiting
  • Institute of Psychiatry and Neurology,
    Warsaw, Mazowieckie 02-957, Poland
    Recruiting
    • Agnieszka Piróg-Balcerzak, MD · Contactaskapb@wp.pl · 48-606-43-15-74
    • Agnieszka Piróg-Balcerzak, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2013
First posted
Jan 7, 2013
Start
Sep 2012
Primary completionEst.
Dec 2014
CompletionEst.
Dec 2014
Last update
Jan 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01761942
Lead sponsor
Institute of Psychiatry and Neurology, Warsaw
Responsible party
Agnieszka Piróg-Balcerzak (MD, psychiatrist, Institute of Psychiatry and Neurology, Warsaw) — Principal investigator
First posted
Jan 7, 2013
Start date
Sep 2012
Primary completion
Dec 2014 (estimated)
Completion
Dec 2014 (estimated)
Last update
Jan 7, 2013

Study contacts

Agnieszka Piróg-Balcerzak, MD
Contact
askapb@wp.pl
48606431574
Agnieszka Piróg-Balcerzak, MD
principal investigator · Institute of Psychiatry and Neurology, Warsaw

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion